Bausch Health Companies Key Executives
This section highlights Bausch Health Companies's key executives, including their titles and compensation details.
Find Contacts at Bausch Health Companies
(Showing 0 of )
Bausch Health Companies Earnings
This section highlights Bausch Health Companies's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-19 | $1.65 | $1.15 |
| Read Transcript | Q3 | 2024 | 2024-10-30 | $1.03 | $1.12 |
| Read Transcript | Q2 | 2024 | 2024-08-01 | $0.88 | $0.89 |
| Read Transcript | Q1 | 2024 | 2024-05-02 | $0.75 | $0.59 |
| Read Transcript | Q4 | 2023 | 2024-02-22 | $1.02 | $1.15 |
| Read Transcript | Q3 | 2023 | 2023-11-02 | $0.92 | $1.03 |
| Read Transcript | Q2 | 2023 | 2023-08-03 | $0.75 | $0.81 |
| Read Transcript | Q1 | 2023 | 2023-05-04 | $0.75 | $0.52 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
$6.81
Stock Price
$2.51B
Market Cap
20.70K
Employees
Laval, QC
Location
Financial Statements
Access annual & quarterly financial statements for Bausch Health Companies, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $9.52B | $8.76B | $8.12B | $8.43B | $8.03B |
| Cost of Revenue | $2.78B | $2.56B | $2.36B | $2.39B | $2.25B |
| Gross Profit | $6.74B | $6.20B | $5.76B | $6.04B | $5.78B |
| Gross Profit Ratio | 70.77% | 70.80% | 70.90% | 71.60% | 71.98% |
| Research and Development Expenses | $616.00M | $604.00M | $529.00M | $465.00M | $452.00M |
| General and Administrative Expenses | $- | $2.27B | $2.11B | $2.11B | $1.92B |
| Selling and Marketing Expenses | $- | $625.00M | $518.00M | $515.00M | $451.00M |
| Selling General and Administrative Expenses | $3.30B | $2.92B | $2.62B | $2.62B | $2.37B |
| Other Expenses | $1.39B | $1.71B | $1.25B | $1.75B | $1.65B |
| Operating Expenses | $5.30B | $5.24B | $4.40B | $4.84B | $4.46B |
| Cost and Expenses | $8.08B | $7.79B | $6.77B | $7.23B | $6.71B |
| Interest Income | $33.00M | $26.00M | $14.00M | $7.00M | $13.00M |
| Interest Expense | $1.39B | $1.33B | $1.46B | $1.43B | $1.53B |
| Depreciation and Amortization | $- | $1.26B | $1.34B | $1.54B | $1.92B |
| EBITDA | $1.55B | $2.24B | $2.62B | $1.94B | $2.55B |
| EBITDA Ratio | 16.24% | 25.61% | 31.82% | 30.65% | 31.37% |
| Operating Income | $1.55B | $963.00M | $1.37B | $1.21B | $676.00M |
| Operating Income Ratio | 16.24% | 11.00% | 16.86% | 14.35% | 8.42% |
| Total Other Income Expenses Net | $-1.38B | $-1.35B | $-1.50B | $-1.47B | $-1.61B |
| Income Before Tax | $167.00M | $-390.00M | $-129.00M | $-1.02B | $-934.00M |
| Income Before Tax Ratio | 1.75% | -4.45% | -1.59% | -12.14% | -11.64% |
| Income Tax Expense | $239.00M | $221.00M | $83.00M | $-87.00M | $-375.00M |
| Net Income | $-46.00M | $-592.00M | $-212.00M | $-937.00M | $-559.00M |
| Net Income Ratio | -0.48% | -6.76% | -2.61% | -11.11% | -6.96% |
| EPS | $1.10 | $-1.62 | $-0.59 | $-2.61 | $-1.57 |
| EPS Diluted | $1.10 | $-1.62 | $-0.59 | $-2.61 | $-1.57 |
| Weighted Average Shares Outstanding | 368.00M | 365.43M | 362.00M | 358.90M | 355.00M |
| Weighted Average Shares Outstanding Diluted | 368.00M | 364.90M | 362.00M | 358.90M | 355.00M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.56B | $2.51B | $2.40B | $2.14B | $2.41B | $2.24B | $2.17B | $1.94B | $2.19B | $2.05B | $1.97B | $1.92B | $2.20B | $2.11B | $2.10B | $2.03B | $2.21B | $2.14B | $1.66B | $2.01B |
| Cost of Revenue | $727.00M | $977.80M | $988.80M | $909.92M | $-1.81B | $623.00M | $649.00M | $582.00M | $652.00M | $584.00M | $577.00M | $551.00M | $626.00M | $582.00M | $612.00M | $574.00M | $645.00M | $590.00M | $495.00M | $519.00M |
| Gross Profit | $1.83B | $1.53B | $1.41B | $1.23B | $4.22B | $1.61B | $1.52B | $1.36B | $1.54B | $1.46B | $1.39B | $1.37B | $1.57B | $1.53B | $1.49B | $1.45B | $1.57B | $1.55B | $1.17B | $1.49B |
| Gross Profit Ratio | 71.59% | 61.00% | 58.80% | 57.50% | 175.30% | 72.20% | 70.10% | 70.10% | 70.30% | 71.50% | 70.70% | 71.30% | 71.50% | 72.40% | 70.90% | 71.70% | 70.85% | 72.40% | 70.25% | 74.20% |
| Research and Development Expenses | $145.00M | $161.00M | $155.97M | $150.33M | $152.00M | $153.00M | $156.00M | $143.00M | $142.00M | $133.00M | $127.00M | $127.00M | $117.00M | $121.00M | $115.00M | $112.00M | $119.00M | $103.00M | $108.00M | $122.00M |
| General and Administrative Expenses | $- | $- | $- | $- | $141.00M | $- | $- | $- | $148.00M | $- | $- | $- | $165.00M | $- | $- | $- | $633.00M | $- | $- | $633.00M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $625.00M | $- | $- | $- | $518.00M | $- | $- | $- | $515.00M | $- | $- | $- | $3.00M | $- | $- | $- |
| Selling General and Administrative Expenses | $820.00M | $850.00M | $831.83M | $790.45M | $766.00M | $715.00M | $711.00M | $725.00M | $666.00M | $661.00M | $676.00M | $622.00M | $680.00M | $653.00M | $685.00M | $606.00M | $636.00M | $572.00M | $526.00M | $633.00M |
| Other Expenses | $309.00M | $- | $-3.00M | $- | $-234.67M | $-60.00M | $-1.33M | $296.00M | $342.00M | $- | $302.00M | $310.00M | $320.00M | $338.00M | $902.00M | $30.00M | $-308.00M | $391.00M | $436.00M | $437.00M |
| Operating Expenses | $1.27B | $996.00M | $987.80M | $940.78M | $918.00M | $1.12B | $1.05B | $1.16B | $1.15B | $1.08B | $1.10B | $1.06B | $1.16B | $1.11B | $1.70B | $1.07B | $1.14B | $1.08B | $1.18B | $1.19B |
| Cost and Expenses | $2.00B | $1.98B | $1.98B | $1.85B | $-896.00M | $1.74B | $1.70B | $1.75B | $1.80B | $1.67B | $1.68B | $1.61B | $1.79B | $1.69B | $2.31B | $1.65B | $1.78B | $1.67B | $1.67B | $1.71B |
| Interest Income | $9.00M | $7.00M | $8.00M | $9.00M | $7.00M | $6.00M | $7.00M | $6.00M | $6.00M | $3.00M | $3.00M | $2.00M | $1.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $2.00M | $7.00M |
| Interest Expense | $337.00M | $346.00M | $350.00M | $355.00M | $363.00M | $339.00M | $319.00M | $307.00M | $307.00M | $385.00M | $410.00M | $362.00M | $343.00M | $351.00M | $364.00M | $368.00M | $379.00M | $374.00M | $385.00M | $396.00M |
| Depreciation and Amortization | $307.00M | $324.59M | $317.93M | $318.57M | $338.09M | $297.18M | $319.16M | $319.02M | $360.54M | $335.00M | $344.04M | $356.32M | $361.78M | $379.40M | $400.57M | $406.01M | $428.00M | $436.00M | $480.00M | $481.00M |
| EBITDA | $853.00M | $647.00M | $718.85M | $606.28M | $836.00M | $310.01M | $741.00M | $490.04M | $310.47M | $713.00M | $622.65M | $639.76M | $857.00M | $942.54M | $97.17M | $181.34M | $422.42M | $918.00M | $435.37M | $782.00M |
| EBITDA Ratio | 33.33% | 25.78% | 30.96% | 28.52% | -129.73% | 30.97% | 34.19% | 24.54% | 32.38% | 35.00% | 32.33% | 32.22% | 33.24% | 37.94% | 9.14% | 37.84% | 22.91% | 40.18% | 25.84% | 39.26% |
| Operating Income | $558.00M | $318.00M | $425.91M | $292.69M | $362.00M | $14.00M | $412.00M | $175.00M | $397.00M | $244.00M | $289.00M | $285.00M | $367.00M | $574.00M | $-270.00M | $-221.00M | $-5.00M | $460.00M | $-27.00M | $248.00M |
| Operating Income Ratio | 21.81% | 12.67% | 17.73% | 13.66% | 15.03% | 0.63% | 19.01% | 9.00% | 18.10% | 11.93% | 14.69% | 14.86% | 16.71% | 27.19% | -12.86% | -10.90% | -0.23% | 21.52% | -1.62% | 12.33% |
| Total Other Income Expenses Net | $-349.00M | $-339.00M | $-341.00M | $-350.00M | $-369.00M | $-340.00M | $-333.00M | $-311.00M | $-121.00M | $195.00M | $-290.00M | $-367.00M | $-346.00M | $-358.00M | $-400.00M | $-370.00M | $-389.00M | $-385.00M | $-410.00M | $-426.00M |
| Income Before Tax | $209.00M | $-21.00M | $47.99M | $-68.69M | $-7.00M | $-326.00M | $79.00M | $-136.00M | $-357.00M | $439.00M | $-129.00M | $-82.00M | $21.00M | $216.00M | $-670.00M | $-591.00M | $-394.00M | $75.00M | $-437.00M | $-178.00M |
| Income Before Tax Ratio | 8.17% | -0.84% | 2.00% | -3.20% | -0.29% | -14.57% | 3.65% | -7.00% | -16.28% | 21.46% | -6.56% | -4.28% | 0.96% | 10.23% | -31.90% | -29.16% | -17.80% | 3.51% | -26.26% | -8.85% |
| Income Tax Expense | $111.00M | $71.57M | $48.99M | $7.96M | $-402.00M | $56.00M | $52.00M | $73.00M | $53.00M | $36.00M | $10.00M | $-16.00M | $-51.00M | $25.00M | $-77.00M | $16.00M | $-242.00M | $5.00M | $-112.00M | $-26.00M |
| Net Income | $93.00M | $-85.00M | $10.00M | $-63.71M | $395.00M | $-378.00M | $26.00M | $-209.00M | $-410.00M | $399.00M | $-139.00M | $-66.00M | $69.00M | $188.00M | $-595.00M | $-610.00M | $-153.00M | $71.00M | $-326.00M | $-152.00M |
| Net Income Ratio | 3.63% | -3.39% | 0.42% | -2.97% | 16.40% | -16.89% | 1.20% | -10.75% | -18.70% | 19.50% | -7.07% | -3.44% | 3.14% | 8.91% | -28.33% | -30.09% | -6.91% | 3.32% | -19.59% | -7.55% |
| EPS | $0.25 | $-0.23 | $0.03 | $-0.17 | $1.08 | $-1.03 | $0.07 | $-0.58 | $-1.13 | $1.10 | $-0.38 | $-0.18 | $0.24 | $0.66 | $-1.66 | $-1.71 | $-0.43 | $0.27 | $-0.92 | $-0.43 |
| EPS Diluted | $0.25 | $-0.23 | $0.03 | $-0.17 | $1.08 | $-1.03 | $0.07 | $-0.58 | $-1.13 | $1.10 | $-0.38 | $-0.18 | $0.24 | $0.66 | $-1.66 | $-1.68 | $-0.43 | $0.27 | $-0.91 | $-0.43 |
| Weighted Average Shares Outstanding | 368.00M | 368.40M | 367.90M | 366.80M | 365.24M | 365.40M | 364.80M | 363.30M | 361.90M | 362.50M | 362.20M | 360.80M | 360.00M | 359.60M | 358.43M | 356.80M | 355.80M | 355.60M | 355.30M | 353.40M |
| Weighted Average Shares Outstanding Diluted | 368.00M | 368.40M | 370.20M | 366.80M | 365.24M | 365.40M | 367.10M | 363.30M | 361.90M | 363.40M | 362.50M | 360.80M | 364.10M | 364.00M | 358.43M | 363.50M | 359.00M | 357.80M | 357.30M | 353.40M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.18B | $947.00M | $564.00M | $582.00M | $605.00M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.18B | $947.00M | $564.00M | $582.00M | $605.00M |
| Net Receivables | $2.14B | $2.00B | $1.79B | $1.77B | $1.58B |
| Inventory | $1.59B | $1.54B | $1.09B | $993.00M | $1.09B |
| Other Current Assets | $858.00M | $1.11B | $803.00M | $2.26B | $2.07B |
| Total Current Assets | $5.77B | $5.60B | $4.25B | $5.61B | $5.34B |
| Property Plant Equipment Net | $1.78B | $1.71B | $1.60B | $1.60B | $1.57B |
| Goodwill | $11.09B | $11.18B | $11.55B | $12.46B | $13.04B |
| Intangible Assets | $5.55B | $6.46B | $5.80B | $6.95B | $8.45B |
| Goodwill and Intangible Assets | $16.64B | $17.64B | $17.35B | $19.41B | $21.49B |
| Long Term Investments | $- | $10.75M | $- | $- | $- |
| Tax Assets | $1.97B | $2.09B | $2.17B | $2.25B | $2.14B |
| Other Non-Current Assets | $363.00M | $307.00M | $326.00M | $340.00M | $664.00M |
| Total Non-Current Assets | $20.75B | $21.75B | $21.44B | $23.59B | $25.86B |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $26.52B | $27.35B | $25.69B | $29.20B | $31.20B |
| Account Payables | $656.00M | $719.00M | $521.00M | $407.00M | $337.00M |
| Short Term Debt | $2.67B | $450.00M | $482.00M | $50.00M | $52.00M |
| Tax Payables | $63.00M | $47.00M | $30.00M | $98.00M | $158.00M |
| Deferred Revenue | $- | $- | $- | $-49.93M | $-52.00M |
| Other Current Liabilities | $3.36B | $3.09B | $2.91B | $4.64B | $4.37B |
| Total Current Liabilities | $6.75B | $4.30B | $3.94B | $5.20B | $4.91B |
| Long Term Debt | $- | $21.94B | $20.52B | $22.87B | $24.15B |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $128.00M | $163.00M | $202.00M | $529.00M | $528.00M |
| Other Non-Current Liabilities | $19.96B | $1.03B | $967.08M | $641.29M | $1.00B |
| Total Non-Current Liabilities | $20.09B | $23.13B | $21.48B | $24.04B | $25.68B |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $26.84B | $27.43B | $25.43B | $29.24B | $30.59B |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $10.49B | $10.42B | $10.39B | $10.32B | $10.23B |
| Retained Earnings | $-9.82B | $-9.78B | $-9.19B | $-8.96B | $-8.01B |
| Accumulated Other Comprehensive Income Loss | $-2.18B | $-1.88B | $-2.06B | $-1.92B | $-2.13B |
| Other Total Stockholders Equity | $234.00M | $214.00M | $159.00M | $462.00M | $454.00M |
| Total Stockholders Equity | $-1.28B | $-1.02B | $-692.00M | $-106.00M | $535.00M |
| Total Equity | $-322.00M | $-82.00M | $260.00M | $-34.00M | $605.00M |
| Total Liabilities and Stockholders Equity | $26.52B | $27.35B | $25.69B | $29.20B | $31.20B |
| Minority Interest | $957.00M | $940.00M | $952.00M | $72.00M | $70.00M |
| Total Liabilities and Total Equity | $26.52B | $27.35B | $25.69B | $29.20B | $31.20B |
| Total Investments | $- | $10.75M | $- | $- | $- |
| Total Debt | $2.67B | $22.39B | $20.77B | $22.65B | $23.93B |
| Net Debt | $1.49B | $21.44B | $20.20B | $22.07B | $23.32B |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.18B | $719.00M | $622.91M | $754.22M | $947.00M | $760.00M | $767.30M | $518.00M | $564.00M | $486.00M | $659.00M | $1.25B | $582.00M | $690.00M | $642.00M | $679.00M | $605.00M | $977.00M | $896.00M | $912.00M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.18B | $719.00M | $622.91M | $754.22M | $947.00M | $760.00M | $767.30M | $518.00M | $564.00M | $486.00M | $659.00M | $1.25B | $582.00M | $690.00M | $642.00M | $679.00M | $605.00M | $977.00M | $896.00M | $912.00M |
| Net Receivables | $2.14B | $2.09B | $2.10B | $2.05B | $2.00B | $1.95B | $1.74B | $1.69B | $1.79B | $1.74B | $1.65B | $1.57B | $1.77B | $1.73B | $1.61B | $1.50B | $1.58B | $1.73B | $1.37B | $1.71B |
| Inventory | $1.59B | $1.66B | $1.61B | $1.63B | $1.54B | $1.27B | $1.64B | $1.22B | $1.09B | $1.06B | $1.07B | $1.04B | $993.00M | $1.06B | $1.09B | $1.08B | $1.09B | $1.22B | $1.23B | $1.12B |
| Other Current Assets | $858.00M | $883.00M | $902.00M | $979.00M | $1.11B | $1.07B | $899.00M | $809.00M | $803.00M | $729.00M | $2.04B | $1.98B | $2.26B | $1.85B | $2.11B | $2.14B | $2.07B | $1.74B | $1.79B | $1.76B |
| Total Current Assets | $5.77B | $5.35B | $5.21B | $5.39B | $5.60B | $5.05B | $5.91B | $4.24B | $4.25B | $4.01B | $5.42B | $5.84B | $5.61B | $5.32B | $5.45B | $5.39B | $5.34B | $5.67B | $5.28B | $5.50B |
| Property Plant Equipment Net | $1.78B | $1.79B | $1.74B | $1.71B | $1.71B | $1.58B | $2.12B | $1.60B | $1.60B | $1.51B | $1.54B | $1.58B | $1.60B | $1.58B | $1.59B | $1.56B | $1.57B | $1.55B | $1.50B | $1.45B |
| Goodwill | $11.09B | $11.17B | $11.13B | $11.15B | $11.18B | $11.19B | $15.41B | $11.58B | $11.55B | $12.04B | $12.27B | $12.43B | $12.46B | $12.48B | $12.53B | $12.48B | $13.04B | $13.16B | $13.08B | $13.03B |
| Intangible Assets | $5.55B | $5.65B | $5.90B | $6.18B | $6.46B | $6.73B | $7.02B | $5.55B | $5.80B | $6.02B | $6.32B | $6.63B | $6.95B | $7.26B | $7.62B | $8.00B | $8.45B | $8.92B | $9.30B | $9.73B |
| Goodwill and Intangible Assets | $16.64B | $16.82B | $17.03B | $17.34B | $17.64B | $17.91B | $22.43B | $17.13B | $17.35B | $18.07B | $18.59B | $19.06B | $19.41B | $19.73B | $20.15B | $20.48B | $21.49B | $22.08B | $22.38B | $22.76B |
| Long Term Investments | $- | $- | $-2.50M | $-17.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $1.97B | $2.19B | $2.19B | $2.15B | $2.10B | $2.19B | $2.90B | $2.16B | $2.17B | $2.37B | $2.28B | $2.28B | $2.25B | $2.27B | $2.25B | $2.15B | $2.14B | $1.91B | $1.87B | $1.74B |
| Other Non-Current Assets | $363.00M | $389.00M | $328.95M | $311.68M | $307.00M | $328.00M | $430.69M | $318.00M | $326.00M | $341.00M | $338.00M | $334.00M | $340.00M | $343.00M | $596.00M | $617.00M | $664.00M | $345.00M | $367.00M | $411.00M |
| Total Non-Current Assets | $20.75B | $21.19B | $21.28B | $21.49B | $21.75B | $22.02B | $27.89B | $21.21B | $21.44B | $22.29B | $22.75B | $23.25B | $23.59B | $23.93B | $24.59B | $24.80B | $25.86B | $25.89B | $26.12B | $26.36B |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $26.52B | $26.54B | $26.49B | $26.89B | $27.35B | $27.06B | $33.80B | $25.45B | $25.69B | $26.30B | $28.17B | $29.09B | $29.20B | $29.25B | $30.04B | $30.20B | $31.20B | $31.56B | $31.40B | $31.86B |
| Account Payables | $656.00M | $667.00M | $579.00M | $642.00M | $719.00M | $569.00M | $515.00M | $561.00M | $521.00M | $486.00M | $536.00M | $471.00M | $407.00M | $455.00M | $442.00M | $342.00M | $337.00M | $379.00M | $447.00M | $444.00M |
| Short Term Debt | $2.67B | $453.00M | $452.00M | $538.00M | $511.00M | $536.00M | $444.00M | $446.00M | $482.00M | $411.00M | $150.00M | $- | $50.00M | $- | $- | $- | $52.00M | $- | $1.00M | $4.00M |
| Tax Payables | $63.00M | $102.00M | $77.99M | $75.92M | $47.00M | $70.00M | $68.91M | $46.00M | $30.00M | $66.00M | $59.00M | $80.00M | $98.00M | $111.00M | $110.00M | $132.00M | $158.00M | $149.00M | $170.00M | $184.00M |
| Deferred Revenue | $- | $- | $77.99M | $75.92M | $2.09B | $2.77B | $2.53B | $- | $- | $1.94B | $- | $- | $-49.93M | $- | $- | $- | $- | $- | $2.17B | $2.38B |
| Other Current Liabilities | $3.36B | $3.28B | $3.26B | $3.15B | $3.02B | $3.05B | $2.94B | $2.87B | $2.91B | $2.87B | $4.25B | $4.22B | $4.64B | $4.87B | $4.96B | $4.42B | $4.37B | $4.20B | $4.10B | $4.25B |
| Total Current Liabilities | $6.75B | $4.51B | $4.37B | $4.40B | $4.30B | $4.22B | $5.26B | $3.92B | $3.94B | $3.83B | $5.00B | $4.77B | $5.20B | $5.44B | $5.52B | $4.90B | $4.91B | $4.73B | $4.72B | $4.89B |
| Long Term Debt | $18.94B | $21.05B | $21.21B | $21.51B | $22.09B | $21.89B | $20.11B | $20.21B | $20.52B | $20.80B | $21.66B | $23.17B | $22.87B | $22.36B | $23.44B | $23.74B | $24.15B | $24.34B | $24.36B | $24.42B |
| Deferred Revenue Non-Current | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $128.00M | $169.00M | $169.98M | $169.82M | $163.00M | $213.00M | $284.92M | $205.00M | $202.00M | $422.00M | $545.00M | $552.00M | $529.00M | $513.00M | $516.00M | $520.00M | $528.00M | $650.00M | $694.00M | $690.00M |
| Other Non-Current Liabilities | $1.02B | $1.05B | $1.15B | $1.14B | $881.76M | $968.00M | $1.16B | $1.17B | $967.08M | $808.00M | $712.00M | $737.00M | $641.29M | $1.08B | $1.18B | $1.17B | $1.00B | $1.18B | $1.08B | $1.07B |
| Total Non-Current Liabilities | $20.09B | $22.28B | $22.35B | $22.66B | $23.13B | $23.07B | $28.18B | $21.38B | $21.48B | $22.03B | $22.92B | $24.46B | $24.04B | $23.95B | $25.14B | $25.42B | $25.68B | $26.18B | $26.13B | $26.19B |
| Other Liabilities | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $26.84B | $26.78B | $26.72B | $27.06B | $27.43B | $27.30B | $33.44B | $25.30B | $25.43B | $25.86B | $27.92B | $29.23B | $29.24B | $29.39B | $30.65B | $30.32B | $30.59B | $30.91B | $30.85B | $31.07B |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $61.14M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $10.49B | $10.49B | $10.48B | $10.47B | $10.42B | $10.42B | $13.80B | $10.40B | $10.39B | $10.39B | $10.38B | $10.37B | $10.32B | $10.31B | $10.30B | $10.29B | $10.23B | $10.22B | $10.22B | $10.21B |
| Retained Earnings | $-9.82B | $-9.92B | $-9.83B | $-9.83B | $-9.78B | $-9.74B | $-12.41B | $-9.39B | $-9.19B | $-8.78B | $-9.18B | $-9.03B | $-8.96B | $-9.03B | $-9.22B | $-8.62B | $-8.01B | $-7.86B | $-7.93B | $-7.61B |
| Accumulated Other Comprehensive Income Loss | $-2.18B | $-1.95B | $-2.01B | $-1.92B | $-1.88B | $-2.05B | $-2.52B | $-1.99B | $-2.06B | $-2.27B | $-2.00B | $-1.97B | $-1.92B | $-1.92B | $-2.18B | $-2.26B | $-2.13B | $-2.21B | $-2.22B | $-2.28B |
| Other Total Stockholders Equity | $234.00M | $201.00M | $181.00M | $163.83M | $214.00M | $190.00M | $188.00M | $171.00M | $159.00M | $129.00M | $104.00M | $415.00M | $462.00M | $437.00M | $413.00M | $393.00M | $454.00M | $435.00M | $411.00M | $396.00M |
| Total Stockholders Equity | $-1.28B | $-1.17B | $-1.17B | $-1.11B | $-1.02B | $-1.18B | $-878.61M | $-800.00M | $-692.00M | $-525.00M | $-693.00M | $-216.00M | $-106.00M | $-204.00M | $-687.00M | $-197.00M | $535.00M | $587.00M | $474.00M | $719.00M |
| Total Equity | $-322.00M | $-242.00M | $-226.97M | $-173.82M | $-82.00M | $-235.00M | $359.13M | $145.00M | $260.00M | $433.00M | $253.00M | $-141.00M | $-34.00M | $-135.00M | $-611.00M | $-124.00M | $605.00M | $655.00M | $546.00M | $790.00M |
| Total Liabilities and Stockholders Equity | $26.52B | $26.54B | $26.49B | $26.89B | $27.35B | $27.06B | $33.80B | $25.45B | $25.69B | $26.30B | $28.17B | $29.09B | $29.20B | $29.25B | $30.04B | $30.20B | $31.20B | $31.56B | $31.40B | $31.86B |
| Minority Interest | $957.00M | $932.00M | $947.86M | $940.03M | $940.00M | $945.00M | $1.24B | $945.00M | $952.00M | $958.00M | $946.00M | $75.00M | $72.00M | $69.00M | $76.00M | $73.00M | $70.00M | $68.00M | $72.00M | $71.00M |
| Total Liabilities and Total Equity | $26.52B | $26.54B | $26.49B | $26.89B | $27.35B | $27.06B | $33.80B | $25.45B | $25.69B | $26.30B | $28.17B | $29.09B | $29.20B | $29.25B | $30.04B | $30.20B | $31.20B | $31.56B | $31.40B | $31.86B |
| Total Investments | $- | $- | $-2.50M | $-17.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $21.62B | $21.51B | $21.66B | $22.05B | $22.39B | $22.43B | $27.24B | $20.65B | $20.77B | $21.21B | $21.81B | $23.17B | $22.65B | $22.36B | $23.44B | $23.74B | $23.93B | $24.34B | $24.36B | $24.43B |
| Net Debt | $20.43B | $20.79B | $21.03B | $21.30B | $21.44B | $21.67B | $26.47B | $20.14B | $20.20B | $20.73B | $21.16B | $21.92B | $22.07B | $21.67B | $22.80B | $23.06B | $23.32B | $23.37B | $23.46B | $23.52B |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-72.00M | $-611.00M | $-212.00M | $-937.00M | $-559.00M |
| Depreciation and Amortization | $1.27B | $1.26B | $1.39B | $1.55B | $1.82B |
| Deferred Income Tax | $66.00M | $51.00M | $-176.00M | $-225.00M | $-475.00M |
| Stock Based Compensation | $150.00M | $132.00M | $126.00M | $128.00M | $105.00M |
| Change in Working Capital | $7.00M | $-582.00M | $-396.00M | $-128.00M | $-366.00M |
| Accounts Receivables | $62.00M | $-195.00M | $-57.00M | $-229.00M | $170.00M |
| Inventory | $-267.00M | $-322.00M | $-198.00M | $-16.00M | $-77.00M |
| Accounts Payables | $357.00M | $158.00M | $-72.03M | $121.00M | $-471.00M |
| Other Working Capital | $-145.00M | $-223.00M | $-68.97M | $-4.00M | $12.00M |
| Other Non Cash Items | $179.00M | $778.00M | $-1.46B | $1.04B | $581.00M |
| Net Cash Provided by Operating Activities | $1.60B | $1.03B | $-728.00M | $1.43B | $1.11B |
| Investments in Property Plant and Equipment | $-337.00M | $-215.00M | $-268.00M | $-283.00M | $-309.00M |
| Acquisitions Net | $- | $-1.89B | $-45.00M | $-14.00M | $16.00M |
| Purchases of Investments | $-12.00M | $-27.00M | $-17.00M | $-19.00M | $-4.00M |
| Sales Maturities of Investments | $14.00M | $26.00M | $22.00M | $42.00M | $8.00M |
| Other Investing Activities | $-119.00M | $-39.00M | $5.00M | $683.00M | $28.00M |
| Net Cash Used for Investing Activities | $-454.00M | $-2.15B | $-303.00M | $409.00M | $-261.00M |
| Debt Repayment | $-799.00M | $1.58B | $-1.01B | $-1.34B | $-2.19B |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $-24.00M | $-31.00M | $-52.00M | $-30.00M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-69.00M | $-106.00M | $-139.00M | $-173.00M | $-107.00M |
| Net Cash Used Provided by Financing Activities | $-868.00M | $1.48B | $-474.00M | $-1.51B | $-2.29B |
| Effect of Forex Changes on Cash | $-36.00M | $9.00M | $-23.00M | $-19.00M | $16.00M |
| Net Change in Cash | $239.00M | $371.00M | $-1.53B | $303.00M | $-1.43B |
| Cash at End of Period | $1.20B | $962.00M | $591.00M | $2.12B | $1.82B |
| Cash at Beginning of Period | $962.00M | $591.00M | $2.12B | $1.82B | $3.24B |
| Operating Cash Flow | $1.60B | $1.03B | $-728.00M | $1.43B | $1.11B |
| Capital Expenditure | $-337.00M | $-272.00M | $-268.00M | $-283.00M | $-309.00M |
| Free Cash Flow | $1.26B | $760.00M | $-996.00M | $1.14B | $802.00M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $98.00M | $-92.00M | $10.00M | $-63.71M | $-47.00M | $-382.00M | $41.51M | $-209.00M | $-410.00M | $403.00M | $-139.00M | $-66.00M | $72.00M | $191.00M | $-593.00M | $-607.00M | $-152.00M | $70.00M | $-325.00M | $-152.00M |
| Depreciation and Amortization | $307.00M | $322.00M | $317.93M | $318.57M | $329.00M | $301.00M | $408.70M | $319.00M | $360.00M | $335.00M | $347.00M | $352.00M | $363.00M | $382.00M | $404.00M | $403.00M | $428.00M | $436.00M | $480.00M | $481.00M |
| Deferred Income Tax | $170.00M | $-3.00M | $-44.10M | $-56.75M | $84.00M | $-3.00M | $-39.76M | $- | $19.00M | $-96.00M | $-16.00M | $-83.00M | $-88.00M | $-17.00M | $-106.00M | $-14.00M | $-262.00M | $-19.00M | $-124.00M | $-70.00M |
| Stock Based Compensation | $43.00M | $38.00M | $36.00M | $33.00M | $29.00M | $29.00M | $33.00M | $41.00M | $35.00M | $33.00M | $26.00M | $32.00M | $33.00M | $33.00M | $31.00M | $31.00M | $24.00M | $27.00M | $27.00M | $27.00M |
| Change in Working Capital | $-116.00M | $126.00M | $31.51M | $-34.84M | $-170.00M | $-148.00M | $-267.35M | $-61.00M | $-22.00M | $-269.00M | $-121.00M | $16.00M | $-217.00M | $-82.00M | $31.00M | $140.00M | $20.00M | $-249.00M | $-9.00M | $-128.00M |
| Accounts Receivables | $-104.00M | $177.65M | $-71.94M | $-62.72M | $-19.00M | $-231.00M | $-73.19M | $108.00M | $-31.00M | $-133.00M | $-90.00M | $197.00M | $-52.00M | $-129.00M | $-108.00M | $60.00M | $103.00M | $-356.00M | $354.00M | $69.00M |
| Inventory | $-49.00M | $-41.83M | $-32.82M | $-143.36M | $-100.00M | $-62.00M | $-38.90M | $-128.00M | $-4.00M | $-56.00M | $-65.00M | $-73.00M | $46.00M | $-15.00M | $-12.00M | $-35.00M | $101.00M | $10.00M | $-94.00M | $-94.00M |
| Accounts Payables | $- | $144.86M | $137.37M | $50.77M | $97.00M | $164.65M | $-98.60M | $-8.00M | $43.44M | $-96.00M | $49.00M | $-75.00M | $-170.00M | $46.00M | $129.10M | $115.00M | $-471.00M | $-842.00M | $-829.00M | $-85.00M |
| Other Working Capital | $37.00M | $-154.69M | $-1.10M | $120.46M | $-148.00M | $-19.65M | $-56.65M | $-33.00M | $-30.44M | $16.00M | $-15.00M | $-33.00M | $-41.00M | $16.00M | $151.00M | $- | $287.00M | $939.00M | $560.00M | $-18.00M |
| Other Non Cash Items | $99.00M | $20.18M | $666.65M | $835.25M | $165.00M | $485.00M | $83.06M | $64.00M | $493.00M | $-1.23B | $26.00M | $-314.00M | $-139.00M | $57.00M | $628.00M | $490.00M | $336.00M | $-9.00M | $151.00M | $103.00M |
| Net Cash Provided by Operating Activities | $601.00M | $411.18M | $378.74M | $206.08M | $390.00M | $282.00M | $268.78M | $154.00M | $475.00M | $-1.26B | $123.00M | $-63.00M | $24.00M | $564.00M | $395.00M | $443.00M | $394.00M | $256.00M | $200.00M | $261.00M |
| Investments in Property Plant and Equipment | $-106.00M | $-69.34M | $-79.03M | $-82.63M | $-144.00M | $-46.00M | $-39.68M | $-51.00M | $-96.00M | $-59.00M | $-56.00M | $-57.00M | $-83.00M | $-68.00M | $-64.00M | $-68.00M | $-84.00M | $-82.00M | $-71.00M | $-72.00M |
| Acquisitions Net | $-91.00M | $-40.16M | $1.00M | $995.53K | $-3.00M | $-1.86B | $849.09K | $-31.00M | $-38.42M | $- | $6.00M | $11.00M | $-5.00M | $7.00M | $-2.00M | $9.00M | $4.00M | $1.00M | $- | $11.00M |
| Purchases of Investments | $-5.00M | $-2.01M | $-2.01M | $-2.99M | $-14.00M | $-2.00M | $3.01M | $-13.00M | $-2.00M | $-1.00M | $-9.00M | $-5.00M | $-5.00M | $-3.00M | $-6.00M | $-5.00M | $-1.00M | $-1.00M | $- | $-2.00M |
| Sales Maturities of Investments | $3.00M | $4.02M | $1.04M | $5.97M | $13.00M | $4.00M | $-2.95M | $11.00M | $2.00M | $7.00M | $7.00M | $6.00M | $31.00M | $3.00M | $6.00M | $2.00M | $1.00M | $1.00M | $4.00M | $2.00M |
| Other Investing Activities | $-1.00M | $5.50M | $43.80K | $5.97M | $27.33K | $11.00M | $1.16M | $6.00M | $-1.58M | $1.00M | $-6.00M | $-11.00M | $-18.00M | $649.00M | $23.00M | $6.00M | $-4.00M | $11.00M | $2.00M | $21.00M |
| Net Cash Used for Investing Activities | $-200.00M | $-102.00M | $-78.96M | $-72.67M | $-148.00M | $-1.89B | $-37.62M | $-78.00M | $-136.00M | $-53.00M | $-58.00M | $-56.00M | $-80.00M | $588.00M | $-43.00M | $-56.00M | $-84.00M | $-70.00M | $-67.00M | $-40.00M |
| Debt Repayment | $95.00M | $-164.00M | $-414.28M | $-313.59M | $-54.60M | $1.87B | $-111.00M | $-124.00M | $-267.00M | $12.34M | $-1.26B | $501.00M | $284.00M | $-1.10B | $-317.02M | $-203.00M | $-501.00M | $-101.00M | $-143.97M | $-1.46B |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $666.55M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $18.00M | $-4.00M | $-14.00M | $-1.00M | $-8.00M | $-3.00M | $-12.00M | $-1.00M | $-1.00M | $-4.00M | $-25.00M | $-4.00M | $-3.00M | $-4.00M | $-41.00M | $- | $-1.00M | $-5.00M | $-24.00M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-10.00M | $-25.00M | $-9.09M | $-26.41M | $-24.40M | $-49.00M | $-9.00M | $-18.00M | $-9.00M | $-47.34M | $634.00M | $-8.00M | $-5.00M | $-51.00M | $-70.98M | $-40.00M | $-2.00M | $-15.00M | $-9.03M | $-59.00M |
| Net Cash Used Provided by Financing Activities | $85.00M | $-189.00M | $-423.37M | $-334.50M | $-79.00M | $1.82B | $-120.00M | $-142.00M | $-276.00M | $-36.00M | $-630.00M | $468.00M | $275.00M | $-1.16B | $-388.00M | $-243.00M | $-503.00M | $-117.00M | $-153.00M | $-1.52B |
| Effect of Forex Changes on Cash | $-35.00M | $13.00M | $-9.00M | $-5.00M | $19.00M | $-17.00M | $1.16M | $6.00M | $31.00M | $-30.00M | $-16.00M | $-8.00M | $-4.00M | $-9.00M | $7.00M | $-13.00M | $21.00M | $12.00M | $4.00M | $-21.00M |
| Net Change in Cash | $451.00M | $127.09M | $-131.31M | $-202.86M | $182.00M | $192.00M | $60.99M | $-60.00M | $94.00M | $-1.38B | $-581.00M | $341.00M | $215.00M | $-14.00M | $-29.00M | $131.00M | $-172.00M | $81.00M | $-16.00M | $-1.32B |
| Cash at End of Period | $1.20B | $750.00M | $622.91M | $754.22M | $962.00M | $780.00M | $779.22M | $531.00M | $591.00M | $497.00M | $1.88B | $2.46B | $2.12B | $1.90B | $1.92B | $1.95B | $1.82B | $1.99B | $1.91B | $1.92B |
| Cash at Beginning of Period | $750.00M | $622.91M | $754.22M | $957.08M | $780.00M | $588.00M | $718.23M | $591.00M | $497.00M | $1.88B | $2.46B | $2.12B | $1.90B | $1.92B | $1.95B | $1.82B | $1.99B | $1.91B | $1.92B | $3.24B |
| Operating Cash Flow | $601.00M | $411.18M | $378.74M | $206.08M | $390.00M | $282.00M | $268.78M | $154.00M | $475.00M | $-1.26B | $123.00M | $-63.00M | $24.00M | $564.00M | $395.00M | $443.00M | $394.00M | $256.00M | $200.00M | $261.00M |
| Capital Expenditure | $-107.00M | $-69.34M | $-79.03M | $-82.63M | $-144.00M | $-46.00M | $-39.68M | $-51.00M | $-96.00M | $-59.00M | $-56.00M | $-57.00M | $-83.00M | $-68.00M | $-64.00M | $-68.00M | $-84.00M | $-82.00M | $-71.00M | $-72.00M |
| Free Cash Flow | $494.00M | $341.84M | $299.71M | $123.45M | $246.00M | $236.00M | $229.09M | $103.00M | $379.00M | $-1.32B | $67.00M | $-120.00M | $-59.00M | $496.00M | $331.00M | $375.00M | $310.00M | $174.00M | $129.00M | $189.00M |
Bausch Health Companies Dividends
Explore Bausch Health Companies's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
4.74x
Bausch Health Companies Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $1 | $1 | November 10, 2010 | November 15, 2010 | December 22, 2010 | November 04, 2010 |
| $0.095 | $0.095 | August 30, 2010 | September 01, 2010 | October 04, 2010 | August 05, 2010 |
| $0.095 | $0.095 | May 28, 2010 | June 02, 2010 | July 05, 2010 | |
| $0.09 | $0.09 | March 04, 2010 | March 08, 2010 | April 05, 2010 | February 24, 2010 |
| $0.09 | $0.09 | November 30, 2009 | December 02, 2009 | January 04, 2010 | November 04, 2009 |
| $0.09 | $0.09 | August 28, 2009 | September 01, 2009 | October 05, 2009 | August 06, 2009 |
| $0.09 | $0.09 | May 13, 2009 | May 15, 2009 | July 06, 2009 | May 06, 2009 |
| $0.375 | $0.375 | March 06, 2009 | March 10, 2009 | April 06, 2009 | February 26, 2009 |
| $0.375 | $0.375 | December 19, 2008 | December 23, 2008 | January 05, 2009 | November 06, 2008 |
| $0.375 | $0.375 | August 21, 2008 | August 25, 2008 | September 03, 2008 | August 13, 2008 |
| $0.375 | $0.375 | May 20, 2008 | May 22, 2008 | May 30, 2008 | May 08, 2008 |
| $0.375 | $0.375 | March 25, 2008 | March 27, 2008 | April 03, 2008 | March 13, 2008 |
| $0.375 | $0.375 | November 16, 2007 | November 20, 2007 | November 30, 2007 | November 08, 2007 |
| $0.375 | $0.375 | August 16, 2007 | August 20, 2007 | August 31, 2007 | August 08, 2007 |
| $0.375 | $0.375 | May 18, 2007 | May 22, 2007 | May 29, 2007 | May 10, 2007 |
| $0.375 | $0.375 | March 22, 2007 | March 26, 2007 | April 03, 2007 | March 15, 2007 |
| $0.5 | $0.5 | January 08, 2007 | January 10, 2007 | January 22, 2007 | December 06, 2006 |
| $0.125 | $0.125 | November 20, 2006 | November 22, 2006 | November 30, 2006 | November 09, 2006 |
| $0.125 | $0.125 | August 16, 2006 | August 18, 2006 | September 01, 2006 | August 10, 2006 |
| $0.125 | $0.125 | May 19, 2006 | May 23, 2006 | May 31, 2006 | May 11, 2006 |
Bausch Health Companies News
Read the latest news about Bausch Health Companies, including recent articles, headlines, and updates.
Bausch Health Announces Pricing of Upsized Private Offering of Senior Secured Notes
LAVAL, QC / ACCESS Newswire / March 25, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has priced its previously announced offering (the "Offering") of $4.4 billion aggregate principal amount of 10.000% senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd. (the "Issuer"), a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Bausch Health Announces Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 21, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that (i) it has delivered conditional notices of redemption for all of its outstanding 5.500% Senior Secured Notes due 2025, 9.000% Senior Notes due 2025, 5.750% Senior Secured Notes due 2027 and 6.125% Senior Secured Notes due 2027 (collectively, the "BHC Notes") and (ii) 1375209 B.C. Ltd., the Company's indirect wholly-owned subsidiary ("HoldCo"), has delivered a conditional notice of redemption for all of its outstanding 9.000% Senior Secured Notes due 2028 (collectively with the BHC Notes, the "Notes").
Bausch Health Announces Launch of Syndication of New Senior Secured Credit Facilities
Transaction is part of a broader refinancing initiative aimed at opportunistically accessing capital markets to address near- and mid-term maturities LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched the syndication of new senior secured credit facilities totaling at least $3.8 billion. The new senior secured credit facilities are expected to consist of (i) a 5-year senior secured revolving credit facility in an amount of at least $400 million (the "New Revolving Facility") and (ii) a $3,400 million 5.5-year secured term loan B facility (the "New Term Loan Facility" and, together with the New Revolving Facility, the "New Senior Secured Credit Facilities") through its indirect wholly-owned subsidiary, 1261229 B.C.
Bausch Health Announces Launch of Private Offering of Senior Secured Notes and Conditional Redemption of Senior Notes
LAVAL, QC / ACCESS Newswire / March 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health") today announced that it has launched an offering (the "Offering") of $4.0 billion aggregate principal amount of new senior secured notes due 2032 (the "Notes") through its indirect wholly-owned subsidiary, 1261229 B.C. Ltd., a company incorporated under the laws of British Columbia, Canada (the "Issuer") that, at the closing of the transactions will be a non-guarantor restricted subsidiary under the indentures that govern the Company's existing senior notes.
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
LAVAL, QC / ACCESS Newswire / March 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, today provided an update on its financing plans. The Company announced that it has engaged J.P.
Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room
Bausch + Lomb reported solid Q4 and full-year 2024 earnings, with CEO Brent Saunders highlighting positives while avoiding the critical issue of Bausch Health's potential sale of its 88% stake. The company's performance review for 2024 was strong, but the future share price trajectory hinges on whether Bausch Health will divest its majority ownership. Investors are closely watching Bausch Health's decision, as it remains the key factor influencing Bausch + Lomb's market valuation and investor sentiment.
Bausch Health Q4 Earnings Recap (Reiterating Buy Rating)
Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally. Key growth drivers include Salix, Xifaxan, and Solta, with a focus on long-term growth and debt management, peaking in 2028. Positive catalysts include FDA litigation outcomes and strategic decisions around Bausch & Lomb, enhancing shareholder value and future revenue potential.
Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Bausch (BHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bausch Health Companies Inc. (BHC) Q4 2024 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Freeman - Raymond James Michael Nedelcovych - TD Cowen Glen Santangelo - Jefferies Operator Greetings. Welcome to the Bausch Health Fourth Quarter 2024 Earnings Call.
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results
Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year period Full-Year Consolidated Revenues of $9.63 billion, up 10% on a Reported basis and 8% on an Organic (non-GAAP)1 basis, with growth in all segments GAAP Net Income Attributable to Bausch Health Companies Inc. of $93 million for the quarter and GAAP Net Loss of $46 million for the year Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $935 million for the quarter, up 8%, and $3.31 billion for the year, up 10% LAVAL, QC / ACCESS Newswire / February 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth quarter and full-year 2024 financial results and other key updates for the quarter. "2024 was a year of delivering on our commitments, where we achieved the high-end of our revenue guidance range, and exceeded our adjusted EBITDA excluding Bausch + Lomb, and adjusted operating cash flow guidance expectations.
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its fourth-quarter and full-year 2024 financial results. “Underpinning our recent success is a commitment to long-term, profitable growth,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “Our refocused pipeline is now filled with promise and potential to significantly enhance the standard of care for pati.
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference
LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference in Miami Beach, Florida on February 24.
Skincare Devices Market and Competition Analysis 2025-2030, Featuring 42 Major Companies Including Alma Lasers, Bausch Health Companies, Lumenis, Merz Pharma & More
Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.
Bausch Health Provides Update on Strategic Alternatives
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation.
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025
LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February 19, 2025. Bausch Health will host a conference call and live webcast at 5:00 p.m.
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website p.
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program
LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for Medicare and Medicaid Services (CMS) has selected XIFAXAN® (rifaximin) 550 mg tablets as one of the medicines for the second round of negotiation as part of the Inflation Reduction Act with an initial price applicability in 2027 of the Drug Price Negotiation program. We look forward to engaging in open and transparent conversations with CMS, where we will share information on the value that XIFAXAN® delivers for the healthcare system in addition to sharing recommendations from The American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) who gave XIFAXAN® the highest possible recommendation (Grade I, A,1) via their practice guidelines.
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?
The mean of analysts' price targets for Bausch (BHC) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, LLC, which is currently developing two innovative therapies for potential use in glaucoma and geographic atrophy (GA). The acquisition strengthens Bausch + Lomb's expanding clinical-stage pipeline. “We're focused on finding treatments that address unmet needs or si.
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire monofocal and toric intraocular lenses (IOLs) in the European Union after receiving a CE Mark late last year. enVista Aspire combines novel Intermediate Optimized optics, which are designed for a broader depth of focus*, with the proven benefits of the enVista® platfor.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for BHC.